Furthermore, PARP inhibitors reduce rDNA transcription and ribosome biogenesis in BRCA1/2-proficient cancer cells by preventing DDX21 ADP-ribosylation, and thereby reduce breast cancer growth (Kim et al. 2019). This evidence concerns the gene PARP1 and breast cancer.